Covid-19 Patients
13
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
87.5%
+1.0% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
Support for COVID19 Patients at Home
Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?
Investigating Long-term Health Effects and Complications in COVID-19 Recoveries
Cupping Therapy on Immune System in Post Covid -19
To Evaluate SSD8432/ Ritonavir in Adults With COVID-19
Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure
Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients
Persistent Dyspnea in Post COVID_19 and Pulmonary Function
Independent Predictors on Clinical Outcomes in SARS-CoV2 Patients
Assessment of the Natural Anticoagulant Profile in Patients With COVID-19
To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)
Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.
To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003